ReviewJournal of neural transmission (Vienna, Austria : 1996)2022
Dopamine transporter (DAT) imaging in Parkinson's disease and related disorders.
Review in Journal of neural transmission (Vienna, Austria : 1996), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.
- Mechanisms and treatments of methamphetamine and HIV-1 co-induced neurotoxicity: a systematic review.Frontiers in immunology · 2024Pooled it
- Visual and Semiquantitative Assessment ofJournal of clinical medicine · 2026Article
- Neuroimaging evidence for a dopamine-independent association between motor cortex microstructure and Parkinson's disease severity.NPJ Parkinson's disease · 2026Article
- Unexpected 123 I FP-CIT (DaT SCAN) Uptake in Palpebral Conjunctival Melanoma.Clinical nuclear medicine · 2026Article
- Comparison betweenQuantitative imaging in medicine and surgery · 2026Article
- Diagnosis and Management of Parkinson Disease in Individuals with Pre-Existing Mood Disorders.International journal of environmental research and public health · 2026Review
- AXIN1 Polymorphisms Potentially Modulate Parkinson's Disease Susceptibility: A Cross-Sectional Study in Northern Han Chinese and White Populations.Neurology and therapy · 2026Article
- Demographics, treatment patterns, and healthcare resource utilization in Parkinson's disease: a real-world data study using a claims database.Arquivos de neuro-psiquiatria · 2026Observational
- Gentiopicroside alleviates neuroinflammation in Parkinson's disease by mediating microglial pyroptosis via the NF-κB/NLRP3/GSDMD pathway.Histology and histopathology · 2025Article
- Stable Dopamine-Signaling mRNA Co-Expression in the Substantia Nigra Is Deregulated in Pathological Conditions, but Not in Dopamine Transporter Knockout Rats.Biomolecules · 2025Article
- Evaluation of damage discrimination in dopaminergic neurons using dopamine transporter PET tracer [EJNMMI research · 2024Article
- Characterization of lipid composition and nutritional quality of yak ghee at different altitudes: A quantitative lipidomic analysis.Food chemistry: X · 2024Article
- Novel perspective of therapeutic modules to overcome motor and nonmotor symptoms in Parkinson's disease.AIMS neuroscience · 2024Review
- Microstructural alterations in white matter and related neurobiology based on the new clinical subtypes of Parkinson's disease.Frontiers in neuroscience · 2024Article
- Imaging Markers in Genetic Forms of Parkinson's Disease.Brain sciences · 2023Review
- Correlations between cerebrospinal fluid homovanillic acid and dopamine transporter SPECT in degenerative parkinsonian syndromes.Journal of neural transmission (Vienna, Austria : 1996) · 2023Article
- Chaudhuri's Dashboard of Vitals in Parkinson's syndrome: an unmet need underpinned by real life clinical tests.Frontiers in neurology · 2023Review
- Pilot study onFrontiers in neurology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This review gives an insight into the beginnings of dopamine transporter (DAT) imaging in the early 1990s, focussing on single photon emission tomography (SPECT). The development of the method and its consolidation as a now widely used clinical tool is described. The role of DAT-SPECT in the diagnosis and differential diagnosis of PD, atypical parkinsonian syndromes and several other different neurological disorders is reviewed. Finally the clinical research using DAT-SPECT as a biomarker for the progression of PD, for the detection of a preclinical dopaminergic lesion and its correlation with neuropathological findings is outlined.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.